Novo Nordisk shares rebound as FDA targets illegal drug copies [BNN Bloomberg (Canada)]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: BNN Bloomberg
The stock plunged nearly eight per cent on Thursday after telehealth company Hims and Hers Health HIMS.N launched a significantly cheaper US$49 compounded version of Novo Nordisk's FDA-approved Wegovy weight-loss pill. Novo's shares, which are near their lowest since Wegovy was introduced in June 2021, were 5.4 per cent higher at 1341 GMT. Late on Thursday, FDA Commissioner Marty Makary said on X that the agency would “take swift action” against companies mass-marketing illegal copycat drugs. “The FDA cannot verify the quality, safety or effectiveness of non-approved drugs,” he said without naming any companies. Despite the FDA statement, Bernstein analyst Christian Moore said he wasn't holding his breath for U.S. authorities to take decisive action. “We do think people will still buy it, and don't think the government will do anything to stop it, based on precedent,” he said. The FDA and individual states share regulatory authority over compounding pharmacies. In September
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk A/S (NYSE:NVO) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d+)" rating to a "hold (c-)" rating.MarketBeat
- TrumpRx: See the 43 drugs available on the Trump administration's new discounted drug site [CBS News]CBS News
- Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore [Yahoo! Finance]Yahoo! Finance
- Hims & Hers shares tick lower after Novo's legal threat [MSNBC.com]MSNBC.com
- Many 2026 Super Bowl ads share a common theme, revealing a truth about America's current mindset By Mae Anderson and The Associated Press By Mae Anderson and The Associated Press February 6, 2026, 2:06 PM ET [Fortune]Fortune
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/5/26 - Form 6-K
- 2/5/26 - Form 6-K
- 2/5/26 - Form 6-K
- NVO's page on the SEC website